Loading…
← CockpitCompetitor Analysis › PPLPHARMA.NS Piramal PharmaOpen in the cockpit ↗

Piramal PharmaPPLPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Contract development and manufacturing (CDMO), complex hospital generics and consumer healthcare businesses, spun off from Piramal Enterprises.

≈ A diversified Indian CDMO plus consumer health armMomentum leader 90
Mkt cap
$3.40B
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$30.7M
20-day average traded
Fwd P/E
150.8×
forward earnings
ROIC−WACC
-14.1 pp
WACC 15.8%
Hurdle
n/a
no reverse DCF
Next earnings
76 days
2 Feb 2027
Close · INR₹238.95
1D-0.7%
1W-2.6%
1M+22.9%
3M+13.5%
6M+37.9%
YTD+38.8%
1Y+22.1%
ATR %3.7%
Beta1.00
52w lowhigh5.9% off high

What Piramal Pharma does

Contract development and manufacturing (CDMO), complex hospital generics and consumer healthcare businesses, spun off from Piramal Enterprises.

Earns most from contract work for drugmakers, paid through development projects and longer manufacturing supply agreements, with plants in India, the UK and North America. Complex hospital generics, such as inhaled anaesthetics, are sold direct to hospitals, and the consumer brands through Indian retail. The Piramal family controls it, with Carlyle as a significant investor.

In one line: A diversified Indian CDMO plus consumer health arm.

Products and services

  • CDMO services
  • Complex hospital generics
  • Consumer healthcare (Little's, Saridon)

Customers

  • Global pharma/biotech (CDMO)
  • Hospitals
  • Retail consumers (OTC brands)

Where it sits in the supply chain

  • CDMO manufacturing
  • Complex hospital generics (inhalation…
  • Consumer healthcare brands

What could go right

  • Global CDMO outsourcing growth
  • Consumer health brand growth

What could go wrong

  • High leverage/legacy debt
  • CDMO client concentration

Moat: narrow (regulatory licence, process know-how). Regulated manufacturing plants and long-term CDMO contracts create switching costs for pharma clients.

Headquarters: Mumbai, India · Founded: 2011 · Employees: 10,440

Named competitors

Piramal Pharma at a glance

Size Piramal Pharma (PPLPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.40B, the 268th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹238.95 on 18 Nov 2026.

Performance Over six months the shares gained 37.9%, against +3.4% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 9.4% over the last twelve months (peer median +10.3%); the operating margin is 3.2% (peer median 12.7%).

Valuation It trades at 150.8× forward earnings against a peer median of 19.6× (most expensive of 14).

Capital Return on invested capital runs 14.1 points below its cost of capital (15.8% WACC).

Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026PPLPHARMA.NS 135Peer median 104
Six months, rebased to 100: Piramal Pharma against the median of its 20 peers (local-currency closes).

Piramal Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹97.8B₹88.7B₹91.5B₹81.7B₹70.8B
Revenue growth—-3%+12%+15%—
Gross profit₹27.1B₹15.4B₹19.6B₹16.8B₹11.0B
EBITDA₹12.0B₹10.00B₹15.2B₹12.6B₹6.41B
Net income-₹2.09B-₹3.26B₹911M₹178M-₹1.86B
Free cash flown/a₹5.10B-₹1.64B-₹1.47B-₹6.76B
Capital expendituren/a₹8.90B₹6.64B₹7.12B₹9.65B
Total debt₹58.7B₹56.7B₹48.6B₹47.1B₹56.4B

Quarterly statements and history in the cockpit →

Piramal Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%+50%2096VRDNAMLX000739VKTX002262688180ARQTACUTAASWOCKPHARMA600511SLS688266LEGNPPLPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Piramal Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×2096000739002262ARQTACUTAASSFZN6005113320688266LEGNPPLPHARMA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Piramal Pharma is the large dot.

Piramal Pharma competitors and peer comparison

Head to head with its named competitors (PPLPHARMA.NS vs SYNGENE.NS vs DIVISLAB.NS vs SAILIFE.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
SAI Life Sciences SAILIFE.NS$4.07B+59%+16%22%87.2×n/a
Laurus Labs LAURUSLABS.NS$13.4B+73%+23%24%76.4×51.2%
Cohance Lifesciences COHANCE.NS$1.87B+7%+14%2%96.3×n/a
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a
Jubilant Pharmova JUBLPHARMA.NS$1.59B-8%+18%7%29.0×n/a

How Piramal Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Piramal Pharma against its 20 peers (data as of 18 Nov 2026)
MeasurePPLPHARMA.NSPeer medianRank in peer set
1-month return+22.9%-1.8%3rd highest of 21
6-month return+37.9%+3.4%5th highest of 20
Distance from 52-week high-5.9%-24.1%3rd highest of 21
Revenue growth (TTM)+9.4%+10.3%9th lowest of 18
Operating margin3.2%12.7%4th lowest of 17
Forward P/E150.8×19.6×most expensive of 14
ROIC minus cost of capital-14.1 pp+4.3 pp2nd lowest of 16
EV / EBITDA30.7×19.8×4th most expensive of 9
Net debt / EBITDA4.2×0.8×2nd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a

Questions

Who are Piramal Pharma's main competitors?
Named competitors: Syngene International (SYNGENE.NS), Divi's Laboratories (DIVISLAB.NS), Catalent (private or unlisted), Sai Life Sciences (SAILIFE.NS), Laurus Labs (LAURUSLABS.NS), Cohance Lifesciences (COHANCE.NS). The cockpit's measured peer set (industry) also includes Simcere Pharmaceutical (2096.HK), Viridian Therapeutics (VRDN), Amylyx Pharmaceuticals (AMLX), Apeloa Pharmaceutical (000739.SZ), Viking Therapeutics (VKTX), Jiangsu Nhwa Pharmaceutical (002262.SZ).
Is Piramal Pharma expensive compared with its peers?
On forward p/e it trades at 150.8× against a peer median of 19.6×, most expensive of 14 in its peer set.
How has Piramal Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +37.9% against +3.4% for the median peer; over one year +22.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.